Notice ID: ac86ce987d584343872ec31937ad31cdAward NoticeAwardedArchived
6505--PET Radiopharmaceuticals Award Notice at Durham VAMC
Awarded on November 5, 2025. Full description on SAM.gov.
Awarded tounder 36C24626D0028 (source: SAM.gov award notice)• $1.9M
Overview
- Posted
- November 6, 2025
- Notice type
- Award Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Veterans Affairs
Notice details
- Office
- 246-NETWORK CONTRACTING OFFICE 6 (36C246)
- Place of performance
- Durham VA Healthcare System 508 Fulton St.
- Last updated
- Nov 6, 2026
- First published
- Last updated on SAM.gov
- Award date
- Nov 5, 2025
- Award amount (SAM.gov award notice)
- $1.9M
Identifiers
- Solicitation number
- 36C24626Q0107
- Notice ID
- ac86ce987d584343872ec31937ad31cd
- Award number (PIID)
- 36C24626D0028
Description
This is a Pre-solicitation notice. This Pre-solicitation notice is not a request for formal proposals or quotes. Solicitation, 36C24626Q0107, will be issued on or about 22 October 2025. The Department of Veterans Affairs, Durham VA Medical, Durham , NC has a requirement for radiopharmaceuticals for Durham VA Medical in Durham , North Carolina. Period of performance will be for a base and four option years.      This acquisition is full and open with NAICS Code 325412 with a size standard of 1,300 Employees. All correspondence and responses shall be via e-mail to Christian.rosadoramirez@va.gov.  Telephone requests for information or questions will NOT be accepted. Â
Award Overview
Award Number
36C24626D0028
Award Amount (SAM.gov award notice)
$1.9M
Award Date
Nov 5, 2025
Awardee
Awardee UEI
Z63RLN31BEE5
Awardee CAGE Code
1TQ01
Awardee Address
KNOXVILLE, TN 37932, TN
Line Item Number
9
Original Solicitation
Notice ID: ac86ce987d584343872ec31937ad31cd
Posted Date: Nov 6, 2025
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $405.8KSigned Nov 3, 2026
- $381.2KSigned Aug 14, 2026
- $379.4KSigned Nov 5, 2025
More From This Vendor
Top 5 most recent
- $288.2KSigned Nov 6, 2026
- —Signed Nov 6, 2026
- $405.8KSigned Nov 3, 2026
- $696.0KSigned Oct 30, 2026
- $241.4KSigned Oct 21, 2026
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
36C24626D0028_1.docx
13 KBAdded in Award Notice version 3Posted
Lifecycle
- 3Version 3Award NoticeArchivedCurrent
6505--PET Radiopharmaceuticals Award Notice at Durham VAMC
Other notices for this solicitation
- Pre-SolicitationRelated noticeOct 22, 2025
6505--PET Radiopharmaceuticals for Durham VAMC
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Emergency Pharmacy Order of DigiFAB | 81% | Sole Source / J&A | Open |
Sources sought notice for VISN 2 Downstate General Radiopharmaceuticals. | 81% | Market Research | 11/17/2026 |
INTENT TO SOLE SOURCE The Department of Veterans Affairs, Network Contracting Office 4 (NCO4) intends to sole source a contract for Lutathera & Pluvicto for the Lebanon VA Medical Center. All work is to be completed in accordance with statement of work. This sole source contract will be solicited and negotiated with Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936-1080 under the deviation outlined in the Revolutionary FAR Overhaul (RFO) for FAR 8.4 - Ordering under the Federal Supply Schedule and GSAM/R 538.71, as required by Executive Order (E.O.) 14275, Restoring Common Sense to Federal Procurement, signed April 15, 2025. Deviation effective date: November 3, 2025. See attached Draft Statement of Work (SOW). The North American Industry Classification System (NAICS) code for this procurement is 325412. The Small Business Administration (SBA) size standard is 1300 employees. Interested vendors that can meet this requirement, shall identify their interest and capability, and respond to this notice by 11/03/2026 by 1400 pm EST. Interested vendors must send a capability statement, no more than one page in length; to include Company Name, SAM UEI Number, Socioeconomic Category, brief description of your business entities capability to handle this project at the Lebanon VA Medical Center. This Special Notice of Intent to Sole Source is for planning purposes only. No solicitation will be made available. This is not a request for quotations. All information shall be provided at no cost or obligation to the Government. Responses must be sent via email to the Contracting Specialist at cynthia.laemmerhirt@va.gov. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon the responses to this notice is solely at the discretion of the Government. If no responses are received, Contracting will proceed with the sole source negotiation with Norvartis Pharmaceuticals Corporation. | 81% | Special Notice | 11/03/2026 |
SOURCES SOUGHT NOTICE (36C25027Q0052) Low Energy Radiopharmaceuticals (Non-FDG F-18 Agents), Unit Doses VA Northeast Ohio Healthcare System (Cleveland, OH) and VA Kent Imaging and Infusion Center (Kent, OH) Notice Type: Sources Sought (Market Research Only) Contracting Office: Department of Veterans Affairs NAICS Code: 325412 Pharmaceutical Preparation Manufacturing Small Business Size Standard: 1,300 employees Product Service Code (PSC): 6505 Drugs and Biologicals Place of Performance: Hot Lab Room B-C432, 10701 East Blvd., Cleveland, OH 44106; and Hot Lab Room B109, 3838 Cascades Blvd., Kent, OH 44240 Anticipated Period of Performance: Base: 01/01/2027 12/31/2027, plus four (4) 12-month option years (through 12/31/2031) Response Due Date/Time: 9:00 AM Eastern Time, Tuesday, November 3, 2026 to: Robert.Blasko@va.gov 1. PURPOSE / DISCLAIMER This is a Sources Sought Notice (SSN) issued for market research purposes only in accordance with FAR Part 10. It is NOT a solicitation, a request for proposal, a request for quotation, or an invitation for bid, and it does not commit the Government to issue a solicitation or award any contract. The Government will not pay for any information submitted in response to this notice, and responses will not be returned. Submitting a response does not guarantee participation in any future solicitation. The purpose of this notice is to identify qualified sources including the extent of participation by Service-Disabled Veteran-Owned Small Businesses (SDVOSBs), Veteran-Owned Small Businesses (VOSBs), and other small business concerns capable of meeting the requirement described below. Responses will assist the Government in determining the appropriate acquisition strategy (including any Veterans First / Rule of Two set-aside determination under VAAR 819.70) and will be used to support acquisition planning under FAR Part 10 and VAAR Part 810. This requirement is being conducted under the VA's health-care-resources sharing authority at 38 U.S.C. 8153 and Public Law 104-262. 2. BACKGROUND AND SCOPE The VA Northeast Ohio Healthcare System and the VA Kent Imaging and Infusion Center require unit-dose, patient-specific low energy radiopharmaceutical products (non-fluorodeoxyglucose F-18 agents) to support routine (non-emergent) and emergent diagnostic nuclear medicine imaging and limited therapeutic procedures. All doses must be compounded and calibrated by or under the supervision of a certified Nuclear Pharmacist and prepared within the required guidelines of the Board of Pharmacy, specifically USP and USP as appropriate. The contractor must follow generally accepted industry standards and the regulations of the applicable governing bodies, which may include the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Food and Drug Administration (FDA), the Nuclear Regulatory Commission (NRC), the Centers for Disease Control and Prevention (CDC), the United States Pharmacopeia (USP), and The Joint Commission (JC). Delivery requirement: The contractor must support both routine and emergent orders (Emergencies). Emergencies may be requested during and outside of regular work hours (Monday through Friday, 06:30 a.m. 4:30 p.m.) and require delivery within 120 minutes after receipt of a phoned, faxed, or electronic order from the VA. The VA also requires prompt processing of Tc-99m tagged white blood cell (WBC) orders. Quantities are estimates and may vary based on patient demand. 3. REQUIRED LICENSURE STATEMENT Interested parties must already possess all licenses, registrations, and authorizations required to receive, possess, compound, prepare, transport, distribute, and dispose of the radioactive byproduct material / radiopharmaceutical isotopes described in this notice, and must be regularly established in the business of providing radionuclides. At a minimum, respondents must hold a current, unrevoked Nuclear Regulatory Commission (NRC) and/or applicable Agreement State radioactive materials license authorizing production and distribution of radiopharmaceuticals for human administration, and the authority to receive and dispose of radioactive waste, together with all applicable FDA, U.S. Department of Transportation (DOT), and state and local authorizations. Respondents should confirm they currently hold such licensure (and, where applicable, identify the issuing authority and license type) as part of their response. Respondents are not required to submit the full license with this SSN but must affirmatively state that current, valid licensure is in place; copies may be required at the solicitation/award stage. 4. ESTIMATED REQUIREMENT (ANNUAL ESTIMATES) The following unit-dose radiopharmaceutical products are required. Quantities are annual estimates based on historical usage for one year and may vary based on patient demand. Item Description Est. Annual Qty 1 99mTc Sulfur Colloid 320 2 99mTc MDP 850 3 99mTc Mebrofenin 110 4 99mTc MAG-3 80 5 99mTc Tetrofosmin 10 6 99mTc MAA 75 7 111In Pentreotide 2 8 99mTc04- (Sodium Pertechnetate) 90 9 99mTc Sestamibi 5,000 10 99mTc White Blood Cell Labeling 90 11 111In White Blood Cell Labeling 2 12 99mTc DTPA 30 40 mCi 60 13 99mTc DTPA 0.4 0.7 mCi 5 14 I-123 Iodine Capsules 200 microcuries 90 15 I-123 Iodine Capsules 2 5 millicuries 12 16 UltraTag Kit 22 17 99mTc Filtered Sulfur Colloid: 0.5 1 millicurie 6 18 123I MIBG dose 2 19 Cold PYP vials 50 20 99mTc PYP 100 21 99mTc DMSA 2 22 67Ga Gallium Citrate 2 23 111In DTPA 2 24 99mTc HMPAO 2 25 131I Diagnostic capsule 10 26 131I Therapeutic capsule 1 3 mCi 12 27 131I Therapeutic capsule, each additional mCi 1,500 28 99mTc HDP 55 29 99mTc WBC Blood Kit (Heparin) 90 Products must be labeled with the radiopharmaceutical identity, amount/activity, concentration, preparation time, calibration time, total volume, expiration date and time, and must include a bar-code label to facilitate scanning into a Nuclear Medicine Information System (NMIS). Each syringe, vial, syringe shield, and vial shield must be correctly labeled. 5. INFORMATION REQUESTED FROM RESPONDENTS Interested and capable firms are invited to submit a response demonstrating their ability to meet this requirement. Responses must include ALL of the following: Manufacturer Authorized Distribution Letter(s) documentation establishing the respondent's authorization to distribute the applicable radiopharmaceutical product(s) (e.g., authorized distributor/dealer letter(s) from the manufacturer(s)). Manufacturer's Name(s) identify the manufacturer(s) of the radiopharmaceutical product(s) the respondent would supply. Business Size and Socioeconomic Status state whether the firm is a large or small business under NAICS 325412 (1,300-employee size standard), and identify all applicable socioeconomic categories (e.g., SDVOSB, VOSB, 8(a), HUBZone, WOSB, SDB, or other). SDVOSBs/VOSBs must be certified in the SBA Veteran Small Business Certification program (via the SBA Search for Certified Businesses (SBS)). Ability to Provide ALL Items state clearly whether the firm can provide ALL of the items listed in Section 4. If the firm can provide only a portion, identify specifically which item(s) it can and cannot supply. GSA / NAC / SAC Availability state whether the item(s) are available on a GSA Schedule, a VA National Acquisition Center (NAC) contract, or a VA Strategic Acquisition Center (SAC) / MSPV contract vehicle, and provide the applicable contract number(s) if so. SAM Unique Entity Identifier (UEI) provide the firm's SAM.gov UEI. Respondents must be actively registered in SAM.gov (www.sam.gov). Current Licensure Confirmation an affirmative statement that the firm currently holds all required NRC and/or Agreement State, FDA, and DOT licenses/authorizations to receive, compound, prepare, transport, distribute, and dispose of the radiopharmaceutical isotopes described herein (see Section 3), including the issuing authority and license type where applicable. Positive Acknowledgement of Delivery Capability a positive, affirmative statement that the firm can deliver in accordance with ALL SOW requirements, including the ability to fulfill emergent orders within 120 minutes of receipt to both the Cleveland and Kent locations, and to provide unit doses compounded/calibrated by or under a certified Nuclear Pharmacist in accordance with USP / and all applicable NRC/FDA/DOT/state regulations. Respondents are encouraged to identify the location(s) of the radiopharmacy(ies) from which they would service both sites. Additional information requested (optional but helpful): company name, address, point of contact (name, title, phone, email); a brief capability statement; and any relevant prior experience providing unit-dose radiopharmaceuticals to federal or commercial healthcare customers. 6. SUBMISSION INSTRUCTIONS Response due date/time: 9:00 AM Eastern Time, Tuesday, November 3, 2026. Responses received after this date and time may not be considered. Format: Submit responses electronically to the Contracting Officer / Contract Specialist identified in the SAM.gov posting (Robert.Blasko@va.gov) . Reference this Sources Sought Notice number (36C25027Q0052) in the subject line. Page/content: Address each item in Section 5, in order. Capability statements should be concise. Questions: Direct any questions to the point of contact listed in the SAM.gov posting (Robert.Blasko@va.gov) prior to the response due date. 7. IMPORTANT NOTES This notice does not restrict the Government to any particular acquisition approach. Based on the responses received, the Government will determine whether the requirement can be set aside for SDVOSBs, VOSBs, or other small business concerns consistent with the Veterans First Contracting Program (VAAR 819.70) and the Rule of Two, or whether another acquisition strategy is appropriate. Respondents are advised that the Nonmanufacturer Rule (13 CFR 121.406) and Limitations on Subcontracting (FAR 52.219-14 / 52.219-33) apply to any resulting SDVOSB/VOSB set-aside or sole-source award above the micro-purchase threshold. Respondents should be prepared to address their status (manufacturer vs. nonmanufacturer) under these rules. All prospective offerors must be registered in SAM.gov to be eligible for any resulting award. The applicable Buy American Act / Trade Agreements Act provisions will apply to any resulting solicitation; respondents may be required to provide a Buy American Act certificate and country-of-origin information at the solicitation stage. THIS IS A SOURCES SOUGHT NOTICE / MARKET RESEARCH ONLY NOT A SOLICITATION. | 78% | Market Research | 11/03/2026 |
THIS REQUEST FOR INFORMATION (RFI) / SOURCES SOUGHT NOTICE IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES. THIS IS NOT A SOLICITATION. SUBMISSION OF INFORMATION ABOUT PRICING, DELIVERY, THE MARKET, AND CAPABILITIES IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI FOR PLANNING PURPOSES IN ACCORDANCE WITH (IAW) FAR 15.201(e). DISCLAIMER This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. SOURCES SOUGHT/RFI DESCRIPTION This is NOT a solicitation announcement. This is a Sources Sought Notice / RFI only. The purpose of this Sources Sought Notice / RFI is to gain information about potential qualified sources and their size classification relative to NAICS 325412 (size standard of 1,300 Employees). Responses to this Sources Sought Notice / RFI will be used by the Government to make appropriate acquisition decisions. After review of the responses to this Sources Sought Notice / RFI, further RFIs and/or a solicitation or other announcements may be published. STATEMENT OF WORK Manufacturing and delivery of sterile/aseptic, USP 825 compliant, low enriched uranium (LEU) radiopharmaceuticals for diagnosis and treatment of patients receiving services at VA San Diego Healthcare System Nuclear Medicine Service. Delivery services must meet all DOT requirements for shipment and delivery of radioactive drugs. Stat delivery services (within 1 hour) must be available 24hrs/day 365 days/year. Companies providing services must provide dose labels compatible with the Nuclear Medicine information System (NMIS) computerized radiopharmacy database. Companies must provide storage, preparation, labeling and delivery of research radiopharmaceuticals as requested. Base January 1, 2027, through December 31, 2027 OY 1 January 1, 2028, through December 31, 2028 OY 2 January 1, 2029, through December 31, 2029 OY 3 January 1, 2030, through December 31, 2030 OY 4 January 1, 2031, through December 31, 2031 PARTICIPATING VA HEALTHCARE SYSTEMS: VA San Diego Healthcare System 3350 La Jolla Village Drive Nuclear Medicine Service San Diego, CA 92161 2. ROUTINE ORDERS Routine orders require delivery the next business day, unless specified elsewhere in this contract. 3. EMERGENCY ORDERS Stat delivery services (within 1 hour) must be available 24hrs/day 365 days/year. 4. PRICE/COST SCHEDULE Description Estimated Min Quantity UOM Unit Price I-123 USP NaI 200 uCi capsules 35 EA I-123 USP NaI 2 mCi 3 EA I-123 USP NaI 4 mCi 3 EA I-123 Iobenguane Sulfate (I-123 Adreview MIBG) 1 I-131 USP NaI DX cap per mCi (4mci) 10 EA I-131 USP NaI TX cap per mCi (150mci) 10 EA In-111 Pentetreotide (Octertide/Octeoscan) UD 1 EA In-111 Pentetate (DTPA) SDV/Vial 1 EA In-111 Autologuous WBCs tagging, pick-up and delivery 9 EA In-111 WBC Blood Kit (Heparin) 9 EA 99mTc Mertiatide (MAG3) UD 38 EA 99mTc Sulfur colloid UD ( Filtered ) 10 EA 99mTc Sulfur colloid UD 90 EA 99mTc Macro Aggregated Albumin (MAA) UD 220 EA 99m Tc High Concentrated (Technegas) 25mCi 150 EA 99m Tc Pentetate (DTPA)UD 1 EA 99mTc dimercaptosuccinic acid (DMSA) UD 1 EA 99mTc Medronate (MDP) UD 300 EA 99mTc Sestamibi (Cardiolite®) UD DO NOT SUBSTITUTE 3400 EA 99mTc PYP or (HDP) 50 EA 99mTc NaTco4 UD per mCi 30 EA 99mTc Mebrofenin (Choletec)UD 25 EA Tl-201 Thallious Chloride UD 1 EA Ga-67 Gallium Citrate UD 1 EA GA-68 DOTATATE (NET-SPOT) 15 EA Macro Aggregated Albumin Vial 0 Pentetate Vial 0 EA Medronate Vial 0 EA Ultra-tag kit 4 Hep-lock for RBC Tag 4 Standard scheduled delivery 3-4 per/day  Stat Delivery Service (within 1 hour) available 24 hours/day 8 After hours call out 4 Heparin vial 4 Heparin/Hetastarch Syringe 9 TOTAL 5. DELIVERY LOCATION, NORMAL WORK HOURS AND INSTRUCTIONS: Delivery Location Nuclear Medicine Service, Main Hospital, 4 West, 4th Floor Normal Work Hours 7:00am to 4:00pm, Monday through Friday 6. PACKAGING AND MARKING a) The contractor shall package, mark and transfer all radioactive material in accordance with all applicable local, state, and federal regulations. b) Items must be properly packaged to prevent damage during shipping, handling, and storage. c) All outer packages must contain the complete purchase number, obligation number and contract number in addition to the shipping address. The purchase number and obligation number will be provided by the individual at the time of ordering. The contract number will be provided upon notice of contract award. d) Packaging List: A packing list/slip shall be enclosed with each shipment indicating the purchase/obligation and delivery order number, contract number, items/quality ordered, and items/quality shipped. 7. RECALLED AND DEFECTIVE PRODUCTS The Contractor will immediately notify the Contracting Officer of any recalls of product or other important product safety issues. As appropriate, the Contractor will replace and/or reimburse recalled / defective products at no cost to the Government. The Contractor may be liable for costs of processing recalls, i.e. administrative and clinical services to replace recalled / defective products. 8. SAFETY GUIDELINES AND REQUIREMENTS The Contractor shall perform all functions of the contract in compliance with Occupational Safety and Health Administration (OSHA), FDA, NRC, Joint Commission safety guidelines and Department of Transportation (DOT) requirements. The Contractor shall self-report any violations to the point of contact (POC) within twenty-four (24) hours. Delivery personnel shall be trained in Radiation Safety Techniques, Nuclear Regulatory Commission, Joint Commission safety guidelines and Department of Transportation requirements. 9. NATIONAL HOLIDAYS OBSERVED BY THE GOVERNMENT New Year s Day January 1 Martin Luther King s Birthday 3rd Monday in January Presidents Day 3rd Monday in February Memorial Day Last Monday in May Juneteenth June 19 Independence Day July 4 Labor Day 1st Monday in September Columbus Day 2nd Monday in October Veterans Day November 11 Thanksgiving Day 4th Thursday in November Christmas Day December 25th The President of the United States of America may declare additional days as a federal holiday, and if so, this holiday will automatically be added to the list above. When a holiday falls on a Sunday, the following Monday shall be observed as a Federal holiday. When a holiday falls on a Saturday, the preceding Friday shall be observed as a Federal Holiday. 10. CONTRACTOR DELIVERY PERSONNEL All contractor personnel are required to wear clothing bearing the name of the Contractor and wear a badge that has the Contractor name. Contractor personnel must have a picture I.D. and must be able to speak English. 11. PARKING AND SPEED LIMIT Park only in areas designated by the Contracting Officer Representative (COR) or otherwise directed by Police and Security Service personnel. The Contractor shall display on each of its vehicles the company name in a size that is clearly visible. Upon receipt of award, the Contractor shall submit a list of employees and vehicles to the COR of each facility. The Contractor shall conform to the speed limit set at each Government facility. Should Contractor personnel receive a citation for parking, speeding or other infraction from VA Security, the offenses will be handled in Federal Court as they are Federal offenses. 12. INVOICE AND PAYMENT No advanced payments will be authorized. The contractor shall submit invoices monthly. The invoice must have at a minimum, the contract number, assigned purchase order, assigned obligation number, date order was placed, date order was shipped, and any additional necessary detailed information to identify service rendered. Payment on invoice may be delayed in invoice(s) are not completed properly. NOTE: Potential quoters must be aware that the items being acquired are procured as Brand Name or Equal. For those items that are or equal , a description of the salient characteristics is outlined below. It is quoter s responsibility to demonstrate its quote meeting the salient physical and functional characteristics included in this solicitation. If the quote does NOT demonstrate, the offer will be considered non-responsive. The interested parties bear full responsibility to ensure their submission demonstrates to the government that they can satisfy the requirement by providing the brand name or equal to the supplies being requested. VAAR 852.212-71 Gray Market and Counterfeit Items clause applies on this acquisition. No remanufacturers or gray market items will be acceptable. Vendor shall be an Original Equipment Manufacturer (OEM), authorized dealer, authorized distributor or authorized reseller verified by an authorization letter or other documents from the OEM signed. The letter must either state specific product(s) quoted or that the quoter is an authorized distributor for all the manufacturer s products. This letter must be on the manufacturer s letterhead and contains the signature of an authorized official for the manufacturer. If the interested contractor fails to provide a signed letter from the OEM (unless the contractor is the OEM), the contractor s response will be deemed non-responsive and will not be considered for award. The list of DRAFT characteristics is intended to be descriptive, not restrictive, of the supplies/services that are required. If your company is interested and capable of providing the required supplies/services, please provide the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: (1) Submit your capabilities statement illustrating how your organization can/cannot meet the list of SOW requirements. For instances where your company cannot meet the SOW requirement(s), please explain. For instances where your company can meet the SOW requirement(s), please show how your company meets/exceeds each requirement. (2) Please review the list of SOW requirements and provide any additional feedback or suggestions. If none, please reply as N/A. (3) Please indicate the size status and representations of your business, such as but not limited to: Service-Disabled Veteran-Owned Small Business (SDVOSB), Veteran-Owned Small Business (VOSB), HUBZone, Woman Owned Small Business (WOSB), Large Business, etc. (4) Is your company considered small under the NAICS code identified in this RFI? (5) Are you the manufacturer, authorized distributor, and/or can your company provide a solution to the required supplies/services described in the list of SOW? (6) If you are a large business, do you have any designated/authorized distributors? If so, please provide their company name, telephone, point of contact and size status (if available). (7) If you re a small business and you are an authorized distributor/reseller for the items identified above, do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified. (8) Limitations on Subcontracting: How does your business ensure compliance with the limitations on subcontracting as outlined in 13 CFR § 125.6? (9) Are the items you are identifying/providing considered Commercial of the Shelf (COTS) items as defined in FAR Part 2.101 under commercial items? (10) Non-Manufacturer Rule: If applicable, can you confirm your business complies with the Non-Manufacturer rule? Specifically, does your company: Provide a product from a small business manufacturer or processor? Not exceed 500 employees? Primarily engage in the retail or wholesale trade and normally sell the type of item being supplied? Take ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice? (11) Please indicate whether your product conforms to the requirements of the Buy American Act? (12) Does your company have a Federal Supply Schedule (FSS) GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract? If so, please provide the contract number(s). (13) If you are an FSS GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract holder, are all the items/solutions you are providing information about available on your schedule/contract? Please state if all or some items are available on the contract. (14) General pricing of your products/solution is encouraged. Pricing will be used for the purpose of market research only. It will not be used to evaluate for any type of award. (15) Please provide your SAM.gov Unique Entity ID/Cage Code number. Responses to this notice shall be submitted via email to Adrienne.Brown4@va.gov. Telephone responses will not be accepted. Responses must be received no later than Friday, November 6, 2026, by 10AM Mountain Time. All responses to this Sources Sought/RFI will be used for planning purposes only. Responses to this Sources Sought Notice / RFI are not considered a request to be added to a prospective bidders list or to receive a copy of the solicitation. If further RFIs and/or a solicitation or other announcement is issued as a result of the information provided from this RFI, all interested parties must respond to the specific posting separately IAW the specifications of that announcement. | 76% | Market Research | 11/06/2026 |
Additional Details
Solicitation Number
36C24626Q0107
Archive Date
Nov 21, 2025
Office Address
HAMPTON, VA, 23667